Alteraciones en la biodistribución de los radiofármacos causadas por interacciones medicamentosas


  1. Hladik WB 3rd, Nigg KK, Rhodes BA. Drug-induced changes in the biologic distribution of radiopharmaceuticals. Semin Nucl Med 1982;12:184-218.
  2. Sampson CB. Patient medication and nuclear medicine tests: A pharmacist’s viewpoint. Nuc Med Commun 1998;19:519-20.
  3. Owunwanne A, Shihab-Eldeen A, Yacoub T, Ziada G. The use of radiopharmaceuticals as an effective toxicologic technique for studying nephrotoxicity of drugs: cyclosporine-A. Hum Exp Toxicol 1998;17:613-9.
  4. Hommeyer SH, Varney DM, Eary JF. Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. J Nucl Med 1992;33:748-50.
  5. Murphy KJ, Line BR, Malfetano J. Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m. Can Assoc Radiol J 1997;48:199-202.
  6. Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993;34:1039-44.
  7. Park CH, Kim HS, Shin HY, Kim HC. Hepatic uptake of Tc-99m MDP on bone scintigraphy from intravenous iron therapy (Blutal). Clin Nucl Med 1997;22:762-4.
  8. Eshima M, Shiozaki H, Ishino Y, Nakata H. Diffuse liver uptake of Tc-99m phosphate compound associated with intravenous injection of iron colloid solution. Clin Nucl Med 1993;18:348-9.
  9. Choy D, Murray IP, Hoschl R. The effect of iron on the biodistribution of bone scanning agents in humans. Radiology 1981;140:197-202.
  10. Cronhjort M, Saaf M, Sjoberg HE, Schnell PO, Jacobsson H. Influence of the phosphate balance on the activity distribution of 99mTc-hydroxy-methylene diphosphonate. Experimental studies in the mouse. Acta Radiol 1998;39:427-33.
  11. Lutrin Cl, Mc Dougall IR, Goris MI. Intense concentration of Tc-99m pyrophosphate in the kidneys of children treated with chemotherapeutic drugs for malignant disease. Radiology 1978;128:165-7.
  12. Malani PN, Depestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA. Experience with community-based amphotericin B infusion therapy. Pharmacotherapy 2005;25:690-7.
  13. Chen WL, Perng MY, Hwei DZ, Yu MD. Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction. J Nucl Biol Med 1994;38(Suppl 1):132-4.
  14. McAfee JG, Singh A, Roskoopf M, Ritter C, Lyons B, Schoonmaker JF. Experimental drug-induced changes in renal function and biodistribution of 99mTc-MDP. Invest Radiol 1983;18:470-8.
  15. Zimmer AM, Pavel DG. Experimental investigations of the possible cause of liver appearance during bone scanning. Radiology 1978;126:813-6.
  16. Palmer AM, Watt I, Dieppe PA. Soft-tissue localization of 99mTc-hydroxymethylene diphosphonate due to interaction with calcium. Clin Radiol 1992;45:326-30.
  17. Schmitt GH, Holmes RA, Isitman AT, Hensley GT, Lewis JD. A proposed mechanism for 99mTc-labeled polyphosphate and diphosphonate uptake by human breast tissue. Radiology 1974;112:733-5.
  18. Hugues FC, Gourlot C, Le Jeunne C. Drug-induced ginecomastia. Ann Med Interne 2000;151:10-7.
  19. Scott S, Alazraki N, Manaster B. Failure of bone scanning to detect fractures in a woman on chronic steroid therapy. Skeletal Radiol 1984;12:204-7.
  20. Van Renterghem D, De Reuck J, Schelstraete K, Elinck W, Van Der Straeten M. Epsilon amino caproic acid myopathy: additional features. Clin Neurol Neurosurg 1984;86:153-7.
  21. Murphy KJ, Line BR, Malfetano J. Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m. Can Assoc Radiol J 1997;48:199-202.
  22. Hiltz A, Iles SE. Abnormal distribution of Tc-99m iminodiphosphonate due to iron dextran therapy. Clin Nucl Med 1990;15:818-20.
  23. Carr EA Jr, Carroll M, Montes M. Effect of vitamin D3, other drugs altering serum calcium or phosphorus concentrations, and desoxycorticosterone on the distribution of Tc-99m pyrophosphate between target and nontarget tissues. J Nucl Med 1981;22:526-34.
  24. Mathov I, Plotkin LI, Sgarlata CL, Leoni J, Bellido T. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res 2001;16:2050-6.
  25. Salgia R, Demetri GD, Kaplan WD. Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report. Cancer 1994;74:1887-90.
  26. Flynn BM, Treves ST. Diffuse hepatic uptake of technetium-99m methylene diphosphonate in a patient receiving high dose methotrexate. J Nucl Med 1987;28:532-4.
  27. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate - a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975;16:744-55.
  28. Eisenberg B, Owens D, Stewart DL, Williamson MR. PYP Maalox localization in liver and spleen. Clin Nucl Med 1989;14:636.
  29. Chacko AK, Gordon DH, Bennett JM, O'Mara RE, Wilson GA. Myocardial imaging with Tc-99m pyrophosphate in patients on adriamycin treatment for neoplasia. J Nucl Med 1977;18:680-3.
  30. Fujita N, Hiroe M, Suzuki Y, Sato H, Inoue Y, Sekiguchi M, et al. A case with cardiac sarcoidosis. Significance of the effect of steroids on the reversion of advanced atrioventricular block and myocardial scintigraphic abnormalities. Heart Vessels Suppl 1990;5:16-8.
  31. Schneider RM, Hayslett JP, Downing SE, Berger HJ, Donabedian RK, Zaret BL Effect of methylprednisolone upon technetium-99m pyrophosphate assessment myocardial necrosis in the canine countershock model. Circulation 1977;56:1029-34.
  32. Candell J, Castell J, Jurado J, López de Sá E, Nuño de la Rosa J, Ortigosa F et al. Guías de actuación clínica de la Sociedad Española de Cardiología. Cardiología nuclear: bases técnicas y aplicaciones clínicas. Rev Esp Cardiol 1999;52:957-989.
  33. Taillefer R, Ahlberg AW, Masood Y, White CM, Lamargese I, Mather JF et al. Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging. J Am Coll Cardiol 2003;42:1475-83.
  34. Narahara KA, Thomson CJ, Hazen JF, Brizendine M, Mena I. The effect of beta blockade on single photon emission computed tomographic (SPECT) thallium-201 images in patients with coronary disease. Am Heart J 1989;117:1030-5.
  35. Sharir T, Rabinowitz B, Livschitz S, Moalem I, Baron J, Kaplinsky E, Chouraqui P. Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs. Jam Coll Cardiol 1998;31:1540-6.
  36. Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 2004;9:243-55.
  37. Fung HL. Clinical pharmacology of organic nitrates. Am J Cardiol 1993;72:9C-13C.
  38. Dewitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev 2004;23:223-38.
  39. Sarin B, Chugh PK, Kaushal D, Soni NL, Sawroop K, Mondal A et al. Sodium bicarbonate-augmented stress thallium myocardial scintigraphy. Eur J Nucl Med Mol Imaging 2004;31:475-81.
  40. Laine H, Sundell J, Nuutila P, Raitakari OT, Luotolahti M, Rönnemaa T. Insulin induced increase in coronary flow reserve is abolished by dexamethasone in young men with uncomplicated type 1 diabetes. Heart 2004;90:270-6.
  41. Waschek J, Hinkle G, Basmadjian G, Allen EW, Ice R. Effect of cardiac drugs on imaging studies with thallous chloride Tl 201. Am J Hosp Pharm 1981;38:1726-8.
  42. Keenan SM, DeLisle RK, Welsh WJ, Paula S, Ball WJ Jr..Elucidation of the Na+, K+-ATPase digitalis binding site. J Mol Graph Model 2005;23:465-75.
  43. Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borges-Neto S, Hollis D et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 2001;49:1023-8.
  44. Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med 1994;21:348-56.
  45. Gilman AG, Rall TW, Nies AS (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (8th ed). Pergamon Press, New York, NY, 1990.
  46. Nascimento Cardoso V, Roca M, Martín-Comín J. No influence of propanolol, cyclosporine, adriamycin, and nifedipine on the in vitro labelling of erythrocytes. Rev Esp Med Nucl 2002;21:24-7.
  47. Porter WC, Dees SM, Freitas JE, Dworkin HJ. Acid-citrate-dextrose compared with heparin in the preparation of in vivo/in vitro technetium-99m red blood cells. J Nucl Med 1983;24:383-7.
  48. Sampson CB. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Safety 1993;8:280-94.
  49. Lee HB, Wexler JP, Scharf SC, Blaufox MD. Pharmacologic alterations in Tc-99m binding by red blood cells: concise communication. J Nucl Med 1983;24:397-401.
  50. White PM, Mann A, Dawn M, Heller GV. Evaluation of 99mTechnetium red blood cells labelling efficiency in adults receiving chemotherapy and the clinical impact in pediatric oncology patients. J Nucl Med Technol 1998;26:265-8.
  51. Sampson CB. Complications and difficulties in radiolabelling blood cells: a review. Nucl Med Commun 1996;17:648-58.
  52. Tatum JL, Burke TS, Hirsch JI, Miler WW, Fratkin MJ. Pitfall to modified in vivo method of technetium-99m red blood cell labeling: Iodinated contrast media. Clin Nucl Med 1983;8:585-7.
  53. Fang GX, Chan PCK, Cheng IKP. Haematological changes after renal transplantation: differences between cyclosporin-A and azathioprine therapy. Int Urol Nephrol 1990;22:181-7.
  54. Mechanick JI. Coombs' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review and discussion of pathogenesis. Mt Sinai J Med 1985;52:667-70.
  55. Stimac D, Milic S, Dintinjana RD, Kovac D, Ristic S. Androgenic/anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002;35:350-2.
  56. Zafrani ES, Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983;143:495-502.
  57. Focal nodular hyperplasia associated with the use of a synthetic anabolic androgen. Am J Gastroenterol 1984;79:150-1.
  58. Mettlin C. Studies on the role of oral contraceptive use in the etiology of benign and malignant liver tumors. J Surg Oncol 1981;18:73-85.
  59. Vana J, Murphy G, Aronoff BL, Baker HW. Primary liver tumors and oral contraceptives. Results of a survey. JAMA 1977;238:2154-8.
  60. Bobinet DD, Sevrin R, Zurbriggen MT, Spolter L, Cohen MB. Lung uptake of 99mTc-sulfur colloid in patient exhibiting presence of Al3+ in plasma. J Nucl Med 1974;15:1220-2.
  61. Malmud LS, Charkes ND, Littlefield J, Reilley J, Stern H, Rosenberg R et al. The mode of action alginic acid compound in the reduction of gastroesophageal reflux. J Nucl Med 1979;20:1023-8.
  62. Malmud LS, Fisher RS. The evaluation of gastroesophageal reflux before and after medical therapies. Semin Nucl Med 1981;11:205-15.
  63. Marano AR, Caride VJ, Prokop EK, Troncale FJ, McCallum RW. Effect of sucralfate and an aluminum hydroxide gel on gastric emptying of solids and liquids. Clin Pharmacol Ther 1985;37:629-32.
  64. Kaplan WD, Drum DE, Lokich JJ. The effect of cancer chemotherapeutic agents on the liver-spleen scan. J Nucl Med 1980;21:84-7.
  65. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001;6:162-76.
  66. Lentle BC, Scott JR, Noujaim AA, Jackson FI . Iatrogenic alterations in radionuclide biodistributions. Semin Nucl Med 1979;9:131-43.
  67. Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr Drug Metab 2004;5:273-82.
  68. Hasan F. Isoflurane hepatotoxicity in a patient with a previous history of halothane-induced hepatitis. Hepatogastroenterology 1998;45:518-22.
  69. Keyes JW Jr, Wilson GA, Quinonest JD. An evaluation of lung uptake of colloid during liver imaging. J Nucl Med 1973;14:687-91.
  70. Beatson N. Atropine and paralytic ileus. Postgrad Med J 1982;58:451-3.
  71. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004;16 (Suppl 2):17-28.
  72. Penagini R, Allocca M, Cantu P, Mangano M, Savojardo D, Carmagnola S. Relationship between motor function of the proximal stomach and transient lower oesophageal sphincter relaxation after morphine. Gut 2004;53:1227-31.
  73. Banzo I. Gammagrafía hepatobiliar: metodología y aplicaciones clínicas. Rev Esp Med Nuclear 1998;17:122-9.
  74. Lorberhoym M, Simon J, Horne T. The role of morphine-augmented cholescintigraphy and real-time ultrasound in detecting gallbladder disease. J Nucl Med Technol 1999;27:294-7.
  75. Pedersen SA, Oster-Jorgensen E, Kraglund K. The effects of morphine on biliary dynamics. A scintigraphic study with 99mTc-HIDA. Scand J Gastroenterol 1987;22:982-6.
  76. Coenegracht JM, Oei TL, van Breda Vriesman PJ. The influence of bilirubin, alcohol and certain drugs on the kinetics of 99mTc-Diethyl IDA (EHIDA) in humans. Eur J Nucl Med 1983;8:140-4.
  77. Shafer RB, Knodell RG, Stanley LN, Elson MK. Acute effects of nicotinic acid on hepatic transport of 99mTc-PIPIDA. Eur J Nucl Med 1983;8:12-4.
  78. Curran TJ, Uzoaru I, Das JB, Ansari G, Raffensperger JG. The effect of cholecystokinin-octapeptide on the hepatobiliary dysfunction caused by total parenteral nutrition. J Pediatr Surg 1995;30:242-6.
  79. Llamas-Elvira JM, Sopena R, Martínez-Paredes M, Jimenez-Hefferman A, González FM, Torres M et al. Muscarinic control of gallbladder dynamics. A study using 99Tcm-HIDA and cholinergic agonists and antagonists. Nucl Med Commun 1990;11:813-7.
  80. Kostrubsky VE, Strom SC, Hanson J, Urda E, Rose K, Burliegh J et al. Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 2003;76:220-8.
  81. Wilkinson NW, Gustafson RJ, Frizzi JD. The effect of erythromycin on bile excretion and proximal small bowel motility following divided gastric bypass surgery: a prospective randomized placebo-controlled trial. Obes Surg 2002;12:765-72.
  82. Patel NJ, Zamek-Gliszcynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ et al. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol Pharmacol 2003;64:154-9.
  83. Majd M, Reba RC, Altman RP. Effect of phenobarbital on 99mTc-IDA scintigraphy in the evaluation of neonatal jaundice. Semin Nucl Med 1981;11:194-204.
  84. Owunwanne A, Shihab-Eldeen A, Yacoub T, Ziada G. The use of radiopharmaceuticals as an effective toxicologic technique for studying nephrotoxicity of drugs: cyclosporine-A. Hum Exp Toxicol 1998;17:613-9.
  85. Lora-Michiels M, Anzola K, Amaya G, Solano M. Quantitative and qualitative scintigraphic measurement of renal function in dogs exposed to toxic doses of Gentamicin. Vet Radiol Ultrasound 2001;42:553-61.
  86. Herzog KM, Deutsch E, Deutsch K, Silberstein EB, Sarangarajan R, Cacini W. Synthesis and renal excretion of technetium-99m-labeled organic cations. J Nucl Med 1992;33:2190-5.
  87. Ludwig V, Martin WH, Delbeke D. Calcium channel blockers: a potential cause of false-positive captopril renography. Clin Nucl Med 2003;28:108-12.
  88. Claveau-Tremblay R, Turpin S, De Braekeleer M, Brassard A, Leblond R. False-positive captopril renography in patients taking calcium antagonists. J Nucl Med 1998;39:1621-6.
  89. Gomes ML, de Mattos DM, de Souza Freitas R, Bezerra RJ, Bernardo-Filho M. Study of the toxicological effect of mitomycin C in mice: alteration on the biodistribution of radiopharmaceuticals used for renal evaluations. Hum Exp Toxicol 2001;20:193-7.
  90. Yee CA, Lee HB, Blaufox MD. Tc-99m DMSA renal uptake: influence of biochemical and physiologic factors. J Nucl Med 1981;22:1054-8.
  91. Green DA, Davies SG. Dimercaptosuccinic acid distribution in renal tubular acidosis. Br J Radiol. 1997;70(840):1291-2.
  92. Acosta Gomez MJ, Llamas Elvira JM, Rodriguez Fernandez A, Gomez Rio M, Lopez Ruiz JM, Muros De Fuentes MA, et al. Diagnosis of renovascular hypertension by pre- and post-captopril renal scintigraphy with 99mTc-DMSA. Rev Esp Med Nucl 2001;20:537-43.
  93. Pelosi E, Masaneo I, Clara R, Valetto MR, Bello M, Zanon C. Technetium-99m labelled macroaggregated albumin arterial catheter perfusion scintigraphy: prediction of gastrointestinal toxicity in hepatic arterial chemotherapy. Eur J Nucl Med 2000;27:668-75.
  94. Basoglu T, Erkan L, Canbaz F, Bernay I, Onen T, Sahin M et al. Transient reverse ventilation-perfusion mismatch in acute pulmonary nitrofurantoin reaction. Ann Nucl Med 1997;11:271-4.
  95. Jankovic DL, Djokic DDj Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide. Nucl Med Commun 2005;26:415-9.
  96. Sovijarvi AR, Poyhonen L, Kellomaki L, Muittari A. Effects of acute and long-term bronchodilator treatment on regional lung function in asthma assessed with krypton-81m and technetium-99m-labelled macroaggregates. Thorax 1982;37:516-20.
  97. Datz FL, Christian PE, Hutson WR, Moore JG, Morton KA. Physiological and pharmacological interventions in radionuclide imaging of the tubular gastrointestinal tract. Semin Nucl Med 1991;21:140-52.
  98. Wang TS, Fawwaz RA, Esser PD, Johnson PM. Altered body distribution of [99mTc] pertechnetate in iatrogenic hyperaluminemia. J Nucl Med 1978;19:381-3.
  99. Duszynski DO, Jewett TC, Allen JE. Tc 99m Na pertechnetate scanning of the abdomen with particular reference to small bowel pathology. Am J Roentgenol Radium Ther Nucl Med 1971;113:258-62.
  100. Francis MD, Slough CL, Tofe AJ. Factors affecting uptake and retention of technetium-99m-diphosphonate and 99m-pertechnetate in osseous, connective and soft tissues. Calcif Tissue Res 1976;20:303-11.
  101. Khettery J, Effmann E, Grand RJ, Treves S. Effect of pentagastrin, histalog, glucagon, secretin, and perchlorate on the gastric handling of 99mTc pertechnetate in mice. Radiology 1976;120:629-31.
  102. Sfakianakis GN, Conway JJ. Detection of ectopic gastric mucosa in Meckel’s diverticulum and other aberrations by scintigraphy: I. Pathophysiology and 10 year clinical experience. J Nucl Med 1981;22:647-54.
  103. Yeker D. Radionuclide imaging of Meckel’s diverticulum: cimetidine versus pentagastrine plus glucagon. Eur J Nucl Med 1984;9:316-9.
  104. Castronuovo JJ, Chervu LR, Milstein DM. Altered distribution of technetium-99m sodium pertechnetate associated with antimicrobial therapy. Clin Nucl Med 1985;10:868-71.
  105. Specht HD, Belsey R, Hanada J. Aluminemic disturbance of technetium-99m DTPA renal function measurement. J Nucl Med 1987;28:383-6.
  106. Inou Y, Momose T, Machida K, Honda N, Mamiya T, Takahashy T. A new method for monitoring the cerebrovascular response to acetazolamide using 99mTc-DTPA-HSA. Radiat Med 1992;10:45-7.
  107. McAfee JG, Thomas FD, Subramanian G, Roskopf M, Hellwing B. Evaluation of cyclosporine nephrotoxicity in rats with various renal radioactive agents. J Nucl Med 1988;29:1577-81.
  108. Gomes ML, de Mattos DM, de Souza Freitas R, Bezerra RJ, Bernardo-Filho M. Study of the toxicological effect of mitomycin C in mice: alteration on the biodistribution of radiopharmaceuticals used for renal evaluations. Hum Exp Toxicol 2001;20:193-7.
  109. Dirlik A, Erinc R, Ozcan Z, Atasever A, Bacakoglu F, Nalbantgil S et al. Technetium-99m-DTPA aerosol scintigraphy in amiodarone induced pulmonary toxicity in comparison with Ga-67 scintigraphy. Ann Nucl Med 2002;16:477-81.
  110. Fischer M, Vetter W, Winterg B, Zidek W, Vetter H. Adrenal scintigraphy in primary aldosteronism. Spironolactone as a cause of incorrect classification between adenoma and hyperplasia. Eur J Nucl Med 1982;7:222-4.
  111. Mila Lopez M, Castell-Conesa J, Pifarre Montaner P, Lorenzo Bosquet C, Garcia-Burillo A, Porta Biosca F. Adrenal cortex scintigraphy with and without dexamethasone suppression in the study of primary aldosteronism. Rev Esp Med Nucl 2004;23:324-9.
  112. Shapiro B, Grekin R, Gross MD, Freitas JE. Interference by spironolactone on adrenocortical scintigraphy and other pitfalls in the location of adrenal abnormalities in primary aldosteronism. Clin Nucl Med 1994;19:441-5.
  113. Gross MD, Valk TW, Swanson DP, Thrall JH, Grekin RJ, Beirewaltes WH. The role of parmacologic manipulation in adrenal cortical scintigraphy. Semin Nucl Med 1981;11:128-48.
  114. Hoefnagel CA, Schornagel J, Valdes Olmos RA. [131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J Nucl Biol Med 1991;35:308-12.
  115. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545-59.
  116. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
  117. Apeldoom L, Voerman HJ, Hoefnagel CA. Interference of MIBG uptake by medication: a case report. Neth J Med 1995;46:239-43.
  118. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30:481-9.
  119. C Sampol Bas; C Peña Viloria. Captación de 123I-MIBG en un hemangioma hepático en el estudio gammagráfico de una lesión suprarrenal. Rev Esp Med Nucl 2005;24:191-4.
  120. Chilton HM, Witcofski RL, Watson NE Jr, Heise CM. Alteration of gallium-67 distribution in tumor bearing mice following treatment with methotrexate: concise comunication. J Nucl Med 1981;22:1064-8.
  121. Lentle BC, Starreveld E, Catz Z, Penney H, Turner AR. Abnormal biodistribution of radiogallium in persons treated with phenytoin. J Can Assoc Radiol 1983;34:114-5.
  122. Khan AS, Dadparvar S, Brown SJ, Slizofski WJ, Roman R, Krishna L, Meihoffer M. The role of gallium-67-citrate in the detection of phenytoin-induced pneumonitis. J Nucl Med 1994;35:471-3.
  123. Moinuddin M. Radionuclide scanning in the detection of drug-induced lung disorders. J Thorac Imaging 1991;6:62-7.
  124. Fukuchi K, Sasaki H, Yokoya T, Noguchi T, Goto Y, Hayashida K et al. Ga-67 citrate and F-18 FDG uptake in spironolactone-induced gynecomastia. Clin Nucl Med 2005;30:105-6.
  125. Kumar M, Abdel-Dayem HM, Naddaf S. Ga-67 uptake by the male breast under digitalis influence (Abstract). Clin Nucl Med 1998;23:779.
  126. Baker DL, Manno CS. Rapid excretion of gallium-67 isotope in an iron-overloaded receiving high–dose intravenous deferoxamine. Am J Hematol 1988;29:230-2.
  127. Loesberg AC, Martin WB. Altered biodistribution of Ga-67 citrate in an iron-overloaded with sickle cell disease. Clin Nucl Med 1994;19:157-9.
  128. Gorenberg M, Groshar D, Even Sapir E. Ga-67 uptake unsuppressed by leukopenia and intense antibiotic therapy. Clin Nucl Med 1992;17:97-8.
  129. Wood BC, Sharman JN, Germann DR, Wood WG, Crouch TT. Gallium citrate Ga 67 imaging in noninfectious interstitial nephritis. Arch Intern Med 1978;138:1665-6.
  130. Handa SP. Drug-induced acute interstitial nephritis: report of 10 cases. CMAJ 1986;135:1278-81.
  131. Hatfield MK, Martin WB, Ryan JW, Vokes EE, Vogelzang NJ. Cardiac gallium uptake in doxorubicin-induced cardiotoxicity. Clin Nucl Med 1986;11:756-7.
  132. Waxman AD, Beldon JR, Richli W, Tanasescu DE, Siemsen JK. Steroid-induced suppression of gallium uptake in tumors of the central nervous system: concise communication. Nucl Med 1978;19:480-2.
  133. Moult RG, Bekerman C. Altered biodistribution of Ga-67 by intramuscular gold salts. Clin Nucl Med 1989;14:831-3.
  134. Noujaim AA, Turner CJ, Scott J. The effect of amphotericin B on 67Ga biodistribution. Int J Nucl Biol 1985;12:70-2.
  135. Bomber P, McReady R, Hammersley P. Propranolol hydrochloride enhancement of tumor perfusion and uptake of galliun-67 in a mouse sarcoma. J Nucl Med 1986;27:243-5.
  136. Brown SJ, Slizofski WJ, Dadparvar S. Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine. J Nucl Med 1990;31:115-7.
  137. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med 2004;45:500-7.
  138. Grayson RR. Factors which influence the radioactive iodine thyroidal uptake test. Am J Med 1960;28:397-415.
  139. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging 2002;29 (Suppl 2):S486-91.
  140. Summary of Product characteristics for Theracap131 TM, capsule.
  141. Yu MD, Shaw SM. Potential interference of agents on radioiodide thyroid uptake in the euthyroid rat. J Nucl Med 2003;44:832-8.
  142. Laurie AJ, Lyon SG, Lasser EC. Contrast material iodides: potential effects on radioactive iodine thyroid uptake. J Nucl Med 1992;33:237-8.
  143. Chung CJ, Hicklin OA, Payan JM, Gordon L.Indium-111-labeled leukocyte scan in detection of synthetic vascular graft infection: the effect of antibiotic treatment. J Nucl Med 1991;32:13-5.
  144. Vandenbroucke-Grauls CM, Thijssen RM, Marcelis JH, Sharma SD, Verhoef J. Effects of lysosomotropic amines on human polymorphonuclear leucocyte function. Immunology 1984;51:319-26.
  145. Challa S, Lyons KP, Broekelschen P, Milne N. Relative sensitivity of Tc-99m WBC versus In-111 WBC in a patient with Crohn disease and steroid use. Clin Nucl Med 1997;22:700-3.
  146. Sampson CB. Complications and difficulties in radiolabelling blood cells: a review. Nucl Med Commun 1996;17:648-58.
  147. Sampson CB. Interference of patient medication in the radiolabelling of white blood cells: an update. Nucl Med Commun 1998;19:529-33.
  148. Dorr U, Rath U, Sautter-Bihl ML, Guzman G, Bach D, Adrian HJ et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993;20:431-3.
  149. Harasko-van der Meer C, Brucke T, Wenger S, Fischer P, Deecke L, Podreka I. Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. J Neural Transm Gen Sect 1993;94:217-21.
  150. Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl) 2004;175:473-80.
  151. Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 2002;162:42-9.
  152. Schwarz J, Oertel WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa. J Nucl Med 1996;37:1112-5.
  153. Ficha técnica de DATSCAN 74MBq/ml (solución inyectable).
  154. Cortés-Blanco A. Especificaciones actuales de la ficha técnica de los radiofármacos fludesoxiglucosa (18F) autorizados para comercialización en España. Seguridad Nuclear 2006;40:20-8.
  155. Blodgett TM, Ames JT, Torok FS, McCook BM. Diffuse bone marrow uptake on whole-body F-18 fluordeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med 2004;29:161-3.
  156. Mayer D, Bednarcczyk EM. Interaction of colony stimulating factors and fluordeoxyglucose F18 positron emission tomography. An Pharmacotherapy 2002;36:1796-9.
  157. Theodore WH, Bairamian D, Newmark ME, DiChiro G, Porter RJ, Larson S, Fishbein D. Effect of phenytoin on human cerebral glucose metabolism. J Cereb Blood Flow 1986;6:315-20.
  158. Roelcke U, Blasberg RG, von Ammon K, Hofer S, Vontobel P, Maguire RP. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 1998;39:879-84.
  159. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 1995;83:657-64.
  160. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996;153:41-9.